Latest twist in pharma love triangle as Teva pursues Mylan merger - MarketWatch
Israel stocks ease; Teva loses patent ruling - MarketWatch
Tel Aviv losing streak extends into third day - MarketWatch
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Warren Buffett's firm trims stakes in drug makers, finance companies - MarketWatch
Teva's stock has tumbled over 8 sessions and Morgan Stanley says it could fall 16% more - MarketWatch
Israel stocks rise, led by Teva, ICL - MarketWatch
Teva Pharmaceuticals reports earnings on Wednesday. Here's what to expect - MarketWatch
Israeli stocks rise; Brainsway, Ratio Oil off - MarketWatch
There's scant evidence so far for chloroquine as a COVID-19 drug — but there's already a shortage - MarketWatch
Billionaire health-care investor Phillip Frost charged by SEC with pump-and-dump schemes - MarketWatch
Teva's stock has tumbled over 8 sessions and Morgan Stanley says it could fall 16% more - MarketWatch
Opinion: Multinationals learn the limits of being big - MarketWatch
Is the new Teva x Ugg collection fashion-forward or just plain ugly? - MarketWatch
Teva Pharmaceutical Settles Opioid Suit With West Virginia - MarketWatch
Teva stock drops on guidance, manufacturing problems - MarketWatch
Teva Pharmaceutical TEVA Pivots Trading Plans and Risk Controls - MarketWatch
Is the new Teva x Ugg collection fashion-forward or just plain ugly? - MarketWatch
What To Do After TEVA Stock Falls Below $10 Again (NYSE:TEVA) | Seeking Alpha
